Prognosis of HIV-associated non-Hodgkin lymphoma in patients starting combination antiretroviral therapy

AIDS

Volumn 23, Issue 15, 2009, Pages 2029-2037

  Bohlius, Julia ^a   Schmidlin, Kurt ^a   Costagliola, Dominique ^a   Fätkenheuer, Gerd ^a   May, Margaret ^a   Murillo, Ana Maria Caro ^a   Mocroft, Amanda ^a   Bonnet, Fabrice ^a   Clifford, Gary ^b   Touloumi, Giota ^a   Miro, Jose M ^a   Chene, Genevieve ^c   Lundgren, Jens ^d   Egger, Matthias ^a   Antinori, Andrea ^a   Boué, François ^a   Brockmeyer, Norbert ^a   Casabona, Jordi ^a   Lopez Guillermo, Armando ^a   Ribera, Josep Maria ^a   Dronda, Fernando ^a   Obel, Niels ^a   Fisher, Martin ^a   Franceschi, Silvia ^a   Gibb, Diana ^a   Le Moing, Vincent ^a   Nadal, David ^a   Prins, Maria ^a   Raffi, François ^a   Roca, Bernardino ^a   Verbon, Annelies ^e   Wolf, Timo ^a   Fortuny, Claudia ^a   Chakraborty, Rana ^a   Minder, Christoph ^a   Sterne, Jonathan ^a   Zwahlen, Marcel ^a   Ellefson, Michelle ^f   Kjaer, Jesper ^f   Collin, Fidéline ^g   Colin, Céline ^g   Weller, Ian ^h   Ledergerber, Bruno ^a   Warszawski, Josiane ^a   Meyer, Laurence ^a   Dabis, François ^a   Krause, Murielle Mary ^a   Goujard, Cecile ^a   Leport, Catherine ^a   de Wolf, Frank ^e   Reiss, Peter ^e   Porter, Kholoud ^a   Dorrucci, Maria ^a   Sabin, Caroline ^a   Del Amo, Julia ^a   Thorne, Claire ^a   Kirk, Ole ^a   Staszewski, Schlomo ^a   Perez Hoyos, Santiago ^a   Almeda, Jesus ^a   D'Arminio Monforte, Antonella ^a   de Martino, Maurizio ^a   Ramos, Jose ⁱ   Battegay, Manuel ^a   Mussini, Cristina ^a   Tookey, Pat ^a   Castagna, Antonella ^a   de Wit, Stephane ^a   Torti, Carlo ^j   Teira, Ramon ^a   Garrido, Myriam ^a   Dedes, Nikos ^a   Phillips, Andrew ^a   Furrer, Hansjakob ^a   Newell, Marie Louise ^a   Telenti, Amalio ^a   Pantazis, Nikos ^a   Lechenadec, Jérôme ^a   Boufassa, Faroudy ^a   Tran, Laurent ^a   Balestre, Eric ^a   Lanoy, Emilie ^a   Couturier, Françoise ^a   Rispens, Theo ^e   Gras, Luuk A J ^e   Bhaskaran, Krishnan ^a   Hill, Teresa ^a   Judd, Ali ^a   Duong, Trinh ^a   Sobrino, Paz ^a   Jennings, Beverley ^a   Bonfigli, Sandro ^a   Cozzi Lepri, Alessandro ^a   Corvasce, Stefano ^a   Adorni, Fulvio ^a   Ridolfo, Anna Lisa ^a   Paraninfo, Giuseppe ^j   Keiser, Olivia ^a   Borghi, Vanni ^a   Masters, Janet ^a   Ortiga, Berta ^a   Stefania, Salpietro ^a   Rickenbach, Martin ^a   Poll, Benedicte ^a   more..

^a CoRIS ^*

^b INTERNATIONAL AGENCY FOR RESEARCH ON CANCER   (France)

^c Bordeaux Regional Co ordinating Center

^d International Agency for Research on Cancer ^*

^e ATHENA

^f Department of Infectious Diseases   (Denmark)

^g ISPED   (France)

^h UNIVERSITY COLLEGE LONDON   (United Kingdom)

ⁱ Madrid Cohort   (Spain)

^j The Italian Master Cohort   (Italy)

more..

Author keywords

Antiretroviral therapy; Cohort studies; Collaborative study; Europe; Mortality; Non Hodgkin lymphoma; Prognosis

Indexed keywords

ADOLESCENT; ADULT; ARTICLE; BRAIN LYMPHOMA; CANCER MORTALITY; CANCER SURVIVAL; CD4 LYMPHOCYTE COUNT; COHORT ANALYSIS; EUROPE; FEMALE; HIGHLY ACTIVE ANTIRETROVIRAL THERAPY; HIV ASSOCIATED NONHODGKIN LYMPHOMA; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; INTRAVENOUS DRUG ABUSE; MAJOR CLINICAL STUDY; MALE; NONHODGKIN LYMPHOMA; PRIORITY JOURNAL; PROGNOSIS; RISK FACTOR; SURVIVAL RATE; SURVIVAL TIME; VIRUS LOAD;

EID: 70349769523     PISSN: 02699370     EISSN: 14735571     Source Type: Journal    
DOI: 10.1097/QAD.0b013e32832e531c     Document Type: Article

References (32)

1. Egger M, Hirschel B, Francioli P, Sudre P, Wirz M, Flepp M, et al. Impact of new antiretroviral combination therapies in HIV infected patients in Switzerland: prospective multicentre study. Swiss HIV Cohort Study. BMJ 1997; 315:1194-1199.
2. Palella FJ Jr, Delaney KM, Moorman AC, Loveless MO, Fuhrer J, Satten GA, et al. Declining morbidity and mortality among patients with advanced human immunodeficiency virus infection. HIV Outpatient Study Investigators. N Engl J Med 1998; 338:853-860.
3. D'Arminio MA, Sabin CA, Phillips A, Sterne J, May M, Justice A, et al. The changing incidence of AIDS events in patients receiving highly active antiretroviral therapy. Arch Intern Med 2005; 165:416-423.
4. Ledergerber B, Telenti A, Egger M. Risk of HIV related Kaposi's sarcoma and non-Hodgkin's lymphoma with potent antiretroviral therapy: prospective cohort study Swiss HIV Cohort Study. BMJ 1999; 319:23-24.
5. International Collaboration on HIV and Cancer. Highly active antiretroviral therapy and incidence of cancer in human immunodeficiency virus-infected adults. J Natl Cancer Inst 2000; 92:1823-1830.
6. EngelsEA, Biggar RJ,HallHI, Cross H,Crutchfield A, FinchJL, et al. Cancer risk in people infected with human immunodeficiency virus in the United States. Int J Cancer 2008; 123:187-194.
7. Bonnet F, Lewden C, May T, Heripret L, Jougla E, Bevilacqua S, et al. Malignancy-related causes of death in human immunodeficiency virus-infected patients in the era of highly active antiretroviral therapy. Cancer 2004; 101:317-324. (Pubitemid 38890835)
8. Lewden C, Salmon D, Morlat P, Bevilacqua S, Jougla E, Bonnet F, et al. Causes of death among human immunodeficiency virus (HIV)-infected adults in the era of potent antiretroviral therapy: emerging role of hepatitis and cancers, persistent role of AIDS. Int J Epidemiol 2005; 34:121-130.
9. Biggar RJ, Engels EA, Ly S, Kahn A, Schymura MJ, Sackoff J, et al. Survival after cancer diagnosis in persons with AIDS. J Acquir Immune Defic Syndr 2005; 39:293-299.
10. Bower M, Gazzard B, Mandalia S, Newsom-Davis T, Thirlwell C, Dhillon T, et al. A prognostic index for systemic AIDS-related non-Hodgkin lymphoma treated in the era of highly active antiretroviral therapy. Ann Intern Med 2005; 143:265-273.
11. Diamond C, Taylor TH, Im T, Anton-Culver H. Presentation and outcomes of systemic non-Hodgkin's lymphoma: A comparison between patients with acquired immunodeficiency syndrome (AIDS) treated with highly active antiretroviral therapy and patients without AIDS. Leuk Lymphoma 2006; 47:1822-1829.
12. The International Non-Hodgkin's Lymphoma Prognostic Factors Project. A predictive model for aggressive non-Hodgkin's lymphoma. N Engl J Med 1993; 329:987-994.
13. Lim ST, Karim R, Tulpule A, Nathwani BN, Levine AM. Prognostic factors in HIV-related diffuse large-cell lymphoma: before versus after highly active antiretroviral therapy. J Clin Oncol 2005; 23:8477-8482.
14. Mounier N, Spina M, Gabarre J, Raphael M, Rizzardini G, Golfier JB, et al. AIDS-related non-Hodgkin lymphoma: final analysis of 485 patients treated with risk-adapted intensive chemotherapy. Blood 2006; 107:3832-3840.
15. Robotin MC, LawMG, Milliken S, Goldstein D, Garsia RJ, Dolan GM, et al. Clinical features and predictors of survival of AIDSrelated non-Hodgkin's lymphoma in a population-based case series in Sydney, Australia. HIV Med 2004; 5:377-384.
16. Collaboration of Observational HIV Epidemiological Research Europe (COHERE) Study Group. Response to combination antiretroviral therapy: variation by age. AIDS 2008; 22: 1463-1473.
17. Kjaer J, Ledergerber B. HIV cohort collaborations: proposal for harmonization of data exchange. Antivir Ther 2004; 9:631-633.
18. Ledergerber B, Egger M, Opravil M, Telenti A, Hirschel B, Battegay M, et al. Clinical progression and virological failure on highly active antiretroviral therapy in HIV-1 patients: A prospective cohort study. Swiss HIV Cohort Study. Lancet 1999; 353:863-868. (Pubitemid 29126872)
19. Revised 1993 classification system for HIV infection and expanded surveillance case definition for AIDS among adolescents and adults. MMWR Recomm Rep 1992; 41(RR-17): 1-19.
20. Miralles P, Berenguer J, Ribera JM, Rubio R, Mahillo B, Tellez MJ, et al. Prognosis of AIDS-related systemic non-Hodgkin lymphoma treated with chemotherapy and highly active antiretroviral therapy depends exclusively on tumorrelated factors. J Acquir Immune Defic Syndr 2007; 44:167-173.
21. Simcock M, Blasko M, Karrer U, Bertisch B, Pless M, Blumer L, et al. Treatment and prognosis of AIDS-related lymphoma in the era of highly active antiretroviral therapy: findings from the Swiss HIV Cohort Study. Antivir Ther 2007; 12:931-939.
22. Hoffmann C, Tiemann M, Schrader C, Janssen D, Wolf E, Vierbuchen M, et al. AIDS-related B-cell lymphoma (ARL): correlation of prognosis with differentiation profiles assessed by immunophenotyping. Blood 2005; 106:1762-1769.
23. Wyen C, Fätkenheuer G, Oette M, Pletternberg A, Rockstroh J, van Lunzen J, et al. Treatment of AIDS-related Lymphoma: Rituximab May Be Beneficial Even in severely Immunosuppressed Patients. In: 15th Conference on Retroviruses and Opportunistic Infections; 2008.
24. Hoffmann C, Wolf E, Fatkenheuer G, Buhk T, Stoehr A, Plettenberg A, et al. Response to highly active antiretroviral therapy strongly predicts outcome in patients with AIDS-related lymphoma. AIDS 2003; 17:1521-1529.
25. Antinori A, Cingolani A, Alba L, Ammassari A, Serraino D, Ciancio BC, et al. Better response to chemotherapy and prolonged survival in AIDS-related lymphomas responding to highly active antiretroviral therapy. AIDS 2001; 15:1483-1491.
26. Boue F, Gabarre J, Gisselbrecht C, Reynes J, Cheret A, Bonnet F, et al. Phase II trial of CHOP plus rituximab in patients with HIV-associated non-Hodgkin's lymphoma. J Clin Oncol 2006; 24:4123-4128.
27. Besson C, Goubar A, Gabarre J, Rozenbaum W, Pialoux G, Chatelet FP, et al. Changes in AIDS-related lymphoma since the era of highly active antiretroviral therapy. Blood 2001; 98:2339-2344.
28. Bower M, Powles T, Nelson M, Mandalia S, Gazzard B, Stebbing J. Highly active antiretroviral therapy and human immunodeficiency virus-associated primary cerebral lymphoma. J Natl Cancer Inst 2006; 98:1088-1091.
29. Kiewe P, Fischer L, Martus P, Thiel E, Korfel A. Primary central nervous system lymphoma: monocenter, long-term, intent-totreat analysis. Cancer 2008; 112:1812-1820.
30. Stebbing J, Mandalia S, Palmieri C, Nelson M, Gazzard B, Bower M. Burkitt's lymphoma and previous AIDS-defining illnesses are not prognostic factors in AIDS-related non- Hodgkin's lymphoma. J Clin Oncol 2005; 23:8538-8540.
31. Straus DJ, Huang J, Testa MA, Levine AM, Kaplan LD. Prognostic factors in the treatment of human immunodeficiency virus-associated non-Hodgkin's lymphoma: Analysis of AIDS Clinical Trials Group protocol 142 - low-dose versus standarddose m-BACOD plus granulocyte-macrophage colonystimulating factor. National Institute of Allergy and Infectious Diseases. J Clin Oncol 1998; 16:3601-3606.
32. Lim ST, Levine AM. Recent advances in acquired immunodeficiency syndrome (AIDS)-related lymphoma. CA Cancer J Clin 2005; 55:229-241.